Castle Biosciences Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 34.2% | 33.3% | 36.4% | 11.9% | 18.3% | 18.6% | 11.6% | 11.4% | 13.7% | 16.9% | 16.3% | 15.5% | 13.3% | 16.2% | 19.2% | 18.4% | 22.1% | 22.1% | 23.9% | 24.8% | 24.2% | 22.1% | 18.4% | 18.8% | 19.0% | 16.7% | 18.2% | 18.7% | 18.6% | 20.5% | 22.5% | 21.0% | 24.5% | 22.9% | 22.7% | |
| 65.8% | 66.7% | 63.6% | 88.1% | 81.7% | 81.4% | 88.4% | 88.6% | 86.3% | 83.1% | 83.7% | 84.5% | 86.7% | 83.8% | 80.8% | 81.6% | 77.9% | 77.9% | 76.1% | 75.2% | 75.8% | 77.9% | 81.6% | 81.2% | 81.0% | 83.3% | 81.8% | 81.3% | 81.4% | 79.5% | 77.5% | 79.0% | 75.5% | 77.1% | 77.3% | |
| 34.5% | 29.1% | 34.9% | 10.0% | 16.0% | 12.3% | 10.3% | 17.9% | 16.7% | 21.3% | 20.1% | 26.5% | 25.9% | 29.8% | 31.9% | 37.7% | 40.1% | 34.2% | 29.5% | 29.5% | 34.2% | 26.5% | 21.0% | 19.7% | 18.9% | 16.2% | 14.4% | 13.5% | 14.3% | 14.8% | 15.6% | 15.5% | 17.2% | 14.0% | 15.5% | |
| 115.6% | 104.5% | 105.6% | 35.7% | 69.4% | 63.5% | 48.2% | 55.9% | 63.6% | 81.7% | 76.9% | 86.5% | 65.6% | 39.3% | 39.8% | 100.5% | 45.6% | 45.7% | 38.5% | 78.7% | 40.0% | 32.8% | 26.2% | 25.9% | 24.6% | 21.2% | 24.1% | 22.7% | 24.8% | 26.6% | 27.8% | 26.8% | 28.5% | 24.3% | 26.7% | |
| 150.1% | 133.7% | 140.4% | 46.4% | 85.4% | 75.8% | 58.5% | 73.8% | 80.3% | 88.2% | 109.4% | 102.1% | 105.5% | 122.5% | 131.2% | 142.2% | 169.2% | 147.9% | 134.3% | 134.7% | 150.8% | 120.1% | 97.3% | 89.8% | 88.5% | 77.6% | 75.9% | 76.6% | 113.1% | 84.5% | 85.7% | 83.3% | 97.5% | 80.1% | 86.2% | |
| -84.3% | -67.0% | -76.8% | 41.7% | -3.7% | 5.7% | 30.0% | 14.8% | 5.9% | -5.1% | -25.6% | -17.5% | -18.8% | -38.7% | -50.3% | -60.6% | -91.3% | -69.9% | -58.2% | -59.6% | -75.0% | -42.2% | -15.7% | -8.6% | -7.5% | 5.8% | 5.9% | 4.7% | -31.7% | -4.9% | -8.2% | -4.4% | -22.0% | -3.0% | -9.0% | |
| 14.5% | 13.2% | 15.3% | 5.7% | 11.8% | 15.8% | 7.4% | 4.3% | 4.4% | 6.0% | 4.6% | 2.3% | 0.0% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.2% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.2% | 0.1% | |
| -99.2% | -79.3% | -92.9% | 33.9% | -15.6% | -11.8% | 39.6% | 12.1% | 3.3% | -10.8% | -30.2% | -27.8% | -18.8% | -38.6% | -50.2% | -60.5% | -91.2% | -10.3% | -54.7% | -53.6% | -69.4% | -37.4% | -11.2% | -3.8% | -3.4% | 9.1% | 9.7% | 9.1% | -29.9% | -0.2% | -0.5% | -3.1% | -17.2% | -1.6% | -5.4% | |
| 13.9% | 14.0% | 14.2% | 0.1% | 11.4% | 9,271.9% | 2,074.3% | 0.4% | 1.7% | 0.3% | 0.1% | 0.5% | 0.0% | 0.0% | 0.1% | -34.8% | 0.5% | -5.6% | -3.9% | 0.1% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% | -1.2% | 7.0% | -2.0% | -0.5% | -5.4% | 0.1% | -0.4% | 0.1% | 0.4% | 0.1% | |
| -99.2% | -79.3% | -92.9% | 33.8% | -15.6% | -11.8% | 39.6% | 11.7% | 3.3% | -10.8% | -30.2% | -28.3% | -18.8% | -38.6% | -50.2% | -25.7% | -91.7% | -4.7% | -54.7% | -53.8% | -69.5% | -37.5% | -11.2% | -3.9% | -3.5% | 10.3% | 2.6% | 11.1% | -29.4% | 5.2% | -0.6% | -2.7% | -17.4% | -2.0% | -5.4% | |
| -82.6% | -64.1% | -75.4% | 40.3% | -2.9% | 4.8% | 47.6% | 17.0% | 8.2% | -4.0% | -24.7% | -24.6% | -17.7% | -35.8% | -45.6% | -54.7% | -83.2% | -2.8% | -46.8% | -46.2% | -62.5% | -31.3% | -6.0% | 1.0% | 1.2% | 13.2% | 14.0% | 15.9% | 4.0% | 3.8% | 4.2% | 1.2% | -12.4% | 2.5% | -0.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.